brentuximab

brentuximab is a topic covered in the Davis's Drug Guide.

To view the entire topic, please sign in or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

General

Genetic Implications:

Pronunciation:
bren-tux-i-mab

Trade Name(s)

Adcetris

Ther. Class.
antineoplastics

Pharm. Class.
drug-antibody conjugates

-- To view the remaining sections of this topic, please sign in or purchase a subscription --

Citation

Quiring, Courtney, et al. "Brentuximab." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109611/all/brentuximab.

Quiring C, Sanoski CA, Vallerand AH. Brentuximab. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109611/all/brentuximab. Accessed January 24, 2019.

Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Brentuximab. In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109611/all/brentuximab

Quiring C, Sanoski CA, Vallerand AH. Brentuximab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 January 24]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109611/all/brentuximab

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - ELEC T1 - brentuximab ID - 109611 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109611/all/brentuximab PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -